×

Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

  • US 9,593,333 B2
  • Filed: 02/14/2014
  • Issued: 03/14/2017
  • Est. Priority Date: 02/14/2013
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating or ameliorating lipoprotein lipase deficiency (LPLD) in an animal comprising administering a therapeutically effective amount of a compound comprising an ApoCIII specific inhibitor to the animal, wherein:

  • administering the compound reduces a triglyceride level by at least 10%, thereby treating or ameliorating LPLD.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×